Clinical trial NCT01078220 - References

Human Papillomavirus Infection — Observational Surveillance Study to Detect Potential Safety Signals in Patients Who Have Had at Least One Dose of GARDASIL™ (V501-031)

Citation(s)

•   Chao C, Klein NP, Velicer CM, Sy LS, Slezak JM, Takhar H, Ackerson B, Cheetham TC, Hansen J, Deosaransingh K, Emery M, Liaw KL, Jacobsen SJ
  Surveillance of autoimmune conditions following routine use of quadrivalent human papillomavirus vaccine. J Intern
•   Klein NP, Hansen J, Chao C, Velicer C, Emery M, Slezak J, Lewis N, Deosaransingh K, Sy L, Ackerson B, Cheetham TC, Liaw KL, Takhar H, Jacobsen SJ
  Safety of quadrivalent human papillomavirus vaccine administered routinely to females. Arch Pediatr Adolesc

A Post-licensure Surveillance Program for the Safety of GARDASIL™ in a Managed Care Organization Setting

Details for clinical trial NCT01078220